Sarah T. Menacho

Sarah T. Menacho

Auto-generated profile, based on publicly available information

Sarah T. Menacho

Department of Neurosurgery, Clinical Neurosciences Center, University of Utah, Salt Lake City, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2018 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
MKMichael Karsy
Michael Karsy
NYNam Yoon
Nam Yoon
LBLillian Boettcher
Lillian Boettcher
RJRandy Jensen
Randy Jensen
LSLubdha Shah
Lubdha Shah
SMSarah T. Menacho
Sarah T. Menacho

6 August 2022 in World Neurosurgery
Verified
Journal Article
Closed access
MAMohammad Azab
Mohammad Azab
NGNicholas Gamboa
Nicholas Gamboa
JNJeffrey Nadel
Jeffrey Nadel
CCChristopher Cutler
Christopher Cutler
JHJeffrey Curran Henson
Jeffrey Curran Henson
MKMichael Karsy
Michael Karsy

18 March 2021 in American Journal of Neuroradiology
Verified
Journal Article
Closed access
PDF file
JMJ.S. McNally
J.S. McNally
ASA. Sakata
A. Sakata
MAMatthew Alexander
Matthew Alexander
LDL.D. Dewitt
L.D. Dewitt
JSJ.A. Sonnen
J.A. Sonnen
AHA.H. de Havenon
A.H. de Havenon
BACKGROUND AND PURPOSE: Cerebral amyloid angiopathy (CAA) is a known risk factor for ischemic stroke though angiographic imaging is often negative. Our goal was to determine the relationship between vessel wall enhancement (VWE) in acute and future ischemic stroke in CAA patients. MATERIALS AND METHODS: This was a retrospective study of patients with new-onset neurologic symptoms undergoing 3T vessel wall MR imaging from 2015 to 2019. Vessel wall enhancement was detected on pre- and postcontrast flow-suppressed 3D T1WI. Interrater agreement was evaluated in cerebral amyloid angiopathy–positive and age-matched negative participants using a prevalence- and bias-adjusted kappa analysis. In patients with cerebral amyloid angiopathy, multivariable Poisson and Cox regression were used to determine the association of vessel wall enhancement with acute and future ischemic stroke, respectively, using backward elimination of confounders to P < .20. RESULTS: Fifty patients with cerebral amyloid angiopathy underwent vessel wall MR imaging, including 35/50 (70.0%) with ischemic stroke and 29/50 (58.0%) with vessel wall enhancement. Prevalence- and bias-corrected kappa was 0.82 (95% CI, 0.71–0.93). The final regression model for acute ischemic stroke included vessel wall enhancement (prevalence ratio = 1.5; 95% CI, 1.1–2.2; P = .022), age (prevalence ratio = 1.02; 95% CI, 1.0–1.05; P = .036), time between symptoms and MR imaging (prevalence ratio = 0.9; 95% CI, 0.8–0.9; P < .001), and smoking (prevalence ratio = 0.7; 95% CI, 0.5–1.0; P = .042) with c-statistic = 0.92 (95% CI, 0.84–0.99). Future ischemic stroke incidence with cerebral amyloid angiopathy was 49.7% (95% CI, 34.5%–67.2%) per year over a total time at risk of 37.5 person-years. Vessel wall enhancement–positive patients with cerebral amyloid angiopathy demonstrated significantly shorter stroke-free survival with 63.9% (95% CI, 43.2%–84.0%) versus 32.2% (95% CI, 14.4%–62.3%) ischemic strokes per year, chi-square = 4.9, P = .027. The final model for future ischemic stroke had a c-statistic of 0.70 and included initial ischemic stroke (hazard ratio = 3.4; 95% CI, 1.0–12.0; P = .053) and vessel wall enhancement (hazard ratio = 2.5; 95% CI, 0.9–7.0; P = .080). CONCLUSIONS: Vessel wall enhancement is associated with both acute and future stroke in patients with cerebral amyloid angiopathy.

22 December 2020 in Journal of Stroke and Cerebrovascular Diseases
Verified
Journal Article
Closed access
SMSarah T. Menacho
Sarah T. Menacho
RGRamesh Grandhi
Ramesh Grandhi
ADAlen Delic
Alen Delic
MAMohammad Anadani
Mohammad Anadani
WZWendy C. Ziai
Wendy C. Ziai
AHAdam de Havenon
Adam de Havenon

1 October 2020 in Journal of Neurosurgery
Verified
Journal Article
Closed access
PDF file
MKMichael Karsy
Michael Karsy
JGJian Guan
Jian Guan
IEIlyas Eli
Ilyas Eli
ABAndrea A. Brock
Andrea A. Brock
SMSarah T. Menacho
Sarah T. Menacho
MPMin S. Park
Min S. Park
OBJECTIVE: Hypovitaminosis D is prevalent in neurocritical care patients, but the potential to improve patient outcome by replenishing vitamin D has not been investigated. This single-center, double-blinded, placebo-controlled, randomized (1:1) clinical trial was designed to assess the effect on patient outcome of vitamin D supplementation in neurocritical care patients with hypovitaminosis D.METHODS: From October 2016 until April 2018, emergently admitted neurocritical care patients with vitamin D deficiency (≤ 20 ng/ml) were randomized to receive vitamin D3 (cholecalciferol, 540,000 IU) (n = 134) or placebo (n = 133). Hospital length of stay (LOS) was the primary outcome; secondary outcomes included intensive care unit (ICU) LOS, repeat vitamin D levels, patient complications, and patient disposition. Exploratory analysis evaluated specific subgroups of patients by LOS, Glasgow Coma Scale (GCS) score, and Simplified Acute Physiology Score (SAPS II).RESULTS: Two-hundred seventy-four patients were randomized (intent-to-treat) and 267 were administered treatment within 48 hours of admission (as-treated; 61.2% of planned recruitment) and monitored. The mean age of as-treated patients was 54.0 ± 17.2 years (56.9% male, 77.2% white). After interim analysis suggested a low conditional power for outcome difference (predictive power 0.12), the trial was halted. For as-treated patients, no significant difference in hospital LOS (10.4 ± 14.5 days vs 9.1 ± 7.9 days, p = 0.4; mean difference 1.3, 95% CI −1.5 to 4.1) or ICU LOS (5.8 ± 7.5 days vs 5.4 ± 6.4 days, p = 0.4; mean difference 0.4, 95% CI −1.3 to 2.1) was seen between vitamin D3 and placebo groups, respectively. Vitamin D3 supplementation significantly improved repeat serum levels compared with placebo (20.8 ± 9.3 ng/ml vs 12.8 ± 4.8 ng/ml, p < 0.001) without adverse side effects. No subgroups were identified by exclusion of LOS outliers or segregation by GCS score, SAPS II, or severe vitamin D deficiency (≤ 10 ng/ml).CONCLUSIONS: Despite studies showing that vitamin D can predict prognosis, supplementation in vitamin D–deficient neurocritical care patients did not result in appreciable improvement in outcomes and likely does not play a role in acute clinical recovery.Clinical trial registration no.: NCT02881957 (clinicaltrials.gov)

4 May 2019 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
BSBrandon A. Sherrod
Brandon A. Sherrod
NGNicholas T. Gamboa
Nicholas T. Gamboa
CWChristopher Wilkerson
Christopher Wilkerson
HWHerschel Wilde
Herschel Wilde
MAMohammed A. Azab
Mohammed A. Azab
SMSarah T. Menacho
Sarah T. Menacho